- Home
- WD vs MLTX Comparison
WD vs MLTX Comparison
Compare WD & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WD
- MLTX
- Stock Information
- Founded
- WD 1937
- MLTX 2021
- Country
- WD United States
- MLTX Switzerland
- Employees
- WD N/A
- MLTX N/A
- Industry
- WD Finance: Consumer Services
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- WD Finance
- MLTX Health Care
- Exchange
- WD Nasdaq
- MLTX Nasdaq
- Market Cap
- WD 2.4B
- MLTX 2.8B
- IPO Year
- WD 2010
- MLTX N/A
- Fundamental
- Price
- WD $86.87
- MLTX $55.89
- Analyst Decision
- WD Buy
- MLTX Strong Buy
- Analyst Count
- WD 2
- MLTX 7
- Target Price
- WD $102.50
- MLTX $74.83
- AVG Volume (30 Days)
- WD 282.9K
- MLTX 463.4K
- Earning Date
- WD 08-07-2025
- MLTX 08-05-2025
- Dividend Yield
- WD 3.26%
- MLTX N/A
- EPS Growth
- WD 25.06
- MLTX N/A
- EPS
- WD 3.24
- MLTX N/A
- Revenue
- WD $1,111,017,000.00
- MLTX N/A
- Revenue This Year
- WD $14.45
- MLTX N/A
- Revenue Next Year
- WD $6.56
- MLTX N/A
- P/E Ratio
- WD $26.83
- MLTX N/A
- Revenue Growth
- WD 15.06
- MLTX N/A
- 52 Week Low
- WD $64.48
- MLTX $31.42
- 52 Week High
- WD $118.19
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- WD 66.65
- MLTX 62.07
- Support Level
- WD $81.99
- MLTX $52.02
- Resistance Level
- WD $86.35
- MLTX $55.81
- Average True Range (ATR)
- WD 2.60
- MLTX 1.83
- MACD
- WD 0.35
- MLTX -0.09
- Stochastic Oscillator
- WD 93.39
- MLTX 95.44
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.